全文获取类型
收费全文 | 172469篇 |
免费 | 13191篇 |
国内免费 | 4845篇 |
专业分类
耳鼻咽喉 | 1095篇 |
儿科学 | 3934篇 |
妇产科学 | 2055篇 |
基础医学 | 10364篇 |
口腔科学 | 3255篇 |
临床医学 | 20746篇 |
内科学 | 25722篇 |
皮肤病学 | 2546篇 |
神经病学 | 7028篇 |
特种医学 | 5512篇 |
外国民族医学 | 47篇 |
外科学 | 27467篇 |
综合类 | 25535篇 |
现状与发展 | 28篇 |
一般理论 | 2篇 |
预防医学 | 6930篇 |
眼科学 | 2251篇 |
药学 | 14117篇 |
118篇 | |
中国医学 | 12623篇 |
肿瘤学 | 19130篇 |
出版年
2024年 | 241篇 |
2023年 | 2866篇 |
2022年 | 4286篇 |
2021年 | 7547篇 |
2020年 | 7188篇 |
2019年 | 6443篇 |
2018年 | 6120篇 |
2017年 | 6418篇 |
2016年 | 6909篇 |
2015年 | 6768篇 |
2014年 | 12283篇 |
2013年 | 15211篇 |
2012年 | 9848篇 |
2011年 | 10561篇 |
2010年 | 8802篇 |
2009年 | 8204篇 |
2008年 | 8013篇 |
2007年 | 8495篇 |
2006年 | 7662篇 |
2005年 | 6794篇 |
2004年 | 5710篇 |
2003年 | 4990篇 |
2002年 | 4159篇 |
2001年 | 3650篇 |
2000年 | 3014篇 |
1999年 | 2405篇 |
1998年 | 2025篇 |
1997年 | 1790篇 |
1996年 | 1540篇 |
1995年 | 1451篇 |
1994年 | 1187篇 |
1993年 | 960篇 |
1992年 | 856篇 |
1991年 | 754篇 |
1990年 | 648篇 |
1989年 | 591篇 |
1988年 | 539篇 |
1987年 | 498篇 |
1986年 | 370篇 |
1985年 | 469篇 |
1984年 | 409篇 |
1983年 | 278篇 |
1982年 | 283篇 |
1981年 | 274篇 |
1980年 | 221篇 |
1979年 | 201篇 |
1978年 | 146篇 |
1977年 | 93篇 |
1976年 | 109篇 |
1975年 | 78篇 |
排序方式: 共有10000条查询结果,搜索用时 359 毫秒
21.
22.
Brittney H. Cotta Margaret F. Meagher Aaron Bradshaw Stephen T. Ryan Gerant Rivera-Sanfeliz 《Expert review of anticancer therapy》2019,19(4):301-308
Introduction: Percutaneous renal mass biopsy has evolved over the last decade with improvements on previous pitfalls including low tissue yield, high non-diagnostic rates, and complications. As understanding of tumor biology and natural history of renal cortical neoplasms has improved, percutaneous renal mass biopsy is poised to have an expanding role in an area characterized by individualized management and refined risk stratification.
Areas covered: This review summarizes the evolution of renal mass biopsy to its current state with respect to outcomes, indications, and clinical guidelines.
Expert opinion: With improved understanding of differential biological potential of renal cortical neoplasms combined with technical improvements in diagnostic yield and accuracy, utilization of renal mass biopsy is becoming an important adjunct to patient care in a broad range of clinical scenarios, including active surveillance, thermal ablation, and use of primary systemic therapy in localized and advanced settings. 相似文献
23.
《Obstetrics, Gynaecology and Reproductive Medicine》2020,30(6):175-183
Menopause is generally experienced as a biopsychosocial process involving physiological changes, and influenced by a wide range of psychological, social and cultural factors. The loss of ovarian oestrogen production may cause debilitating symptoms, including hot flushes, night sweats, sleep disturbance, vaginal dryness, dyspareunia, bladder dysfunction, loss of libido, and mood changes. Experience of the menopause transition varies widely between individuals, depending on the age of onset, personal health and wellbeing, social context, environment and culture.Hormone Replacement Therapy (HRT) remains the most effective treatment for the management of vasomotor symptoms and vaginal dryness, but has no proven role in the treatment of chronic diseases of ageing. Treatment should be individualized, and for most healthy women aged 50–59 years the risks of HRT are low. An understanding of the pathophysiology of menopausal symptoms and the risks and benefits of both hormonal and non-hormonal treatments assists in the individual management of patients. 相似文献
24.
25.
26.
27.
28.
29.
《Journal of thoracic oncology》2020,15(4):618-627
IntroductionPembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC.MethodsEligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)–positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review.ResultsEighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5–48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4–29.4); two patients had complete response (one with a PD-L1–positive tumor), and 14 patients had partial response (13 with PD-L1–positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events.ConclusionsPembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated. 相似文献
30.